4.6 Article

Immunostimulatory cytokine and doxorubicin co-loaded nanovesicles for cancer immunochemotherapy

期刊

出版社

ELSEVIER
DOI: 10.1016/j.nano.2019.02.008

关键词

Cytokine; Nanovesicles; Immunochemotherapy; Combinational therapy; Cancer

资金

  1. National Natural Science Foundation of China [81673374, 81872810]
  2. Fundamental Research Funds for the Central Universities [2018KFYYXJJ019]
  3. Wuhan Science and Technology Plan for Applied Fundamental Research [2017060201010146]

向作者/读者索取更多资源

Taking advantages of drug delivery system, immunostimulatory and chemotherapeutic agents with different physiochemical properties can be co-delivered to realize synergistic antitumor effect. Here the immunostimulatory cytokine interleukin-2 (IL-2) was firstly adsorbed in doxorubicin (DOX) loaded nanovesicles (NV-DOXIL-2) with high encapsulation efficiency by a facile solvent free method. After intravenous injection to melanoma bearing mice, NV-DOXIL-2 can accumulate in tumor and remarkably suppress tumor growth with negligible systemic toxicity. To extend the comprehensive application of this strategy. interferon-gamma (IFN-gamma) was further introduced to the combinatorial system to develop cytokine cocktails adsorbed NVs. This kind of NVs can significantly inhibit the primary tumor growth and lung metastasis of triple-negative breast cancer. With exploration of underlying mechanism, the cytokine cocktails adsorbed NVs can facilitate maturation of dendritic cells, promote the infiltration and activation of CD8(+) T lymphocytes and natural killer cells, and increase the recruitment of CD45(+) immune cells and Ly6G(+) neutrophils. (C) 2019 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据